AC
MRVI icon

Armistice Capital’s Maravai LifeSciences MRVI Stock Holding History

Armistice Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-168,000
Closed -$8.24M – 163
2021
Q3 		$8.24M Buy
+168,000
New +$8.19M 0.14% 93

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Armistice Capital's MRVI Position: Q4 2021 in Review

Armistice Capital sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 168,000 shares — an estimated $8.24M sold.

Armistice Capital first reported a position in MRVI in Q3 2021 and held it in 1 quarter. The position peaked at $8.24M in Q3 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

  • Armistice Capital reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
  • Armistice Capital sold 168,000 Maravai LifeSciences shares in Q4 2021, an estimated $8.24M.
  • Armistice Capital first reported a position in Maravai LifeSciences in Q3 2021 and held it in 1 quarter.
  • Armistice Capital's Maravai LifeSciences position peaked at $8.24M in Q3 2021.
  • 229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on Armistice Capital's 13F filing for Q4 2021, filed 14 Feb 2022.